Welcome to
HabPharmaceuticals
LOADING
Manufacturing Units:
HAB Pharma operates three manufacturing units across two locations: Vasai, Mumbai, and Selaqui, Dehradun, with the latter comprising two distinct units (Unit 2 and Unit 3). Together, these facilities include six production blocks and employ 616 people on roll.
Dosage forms handled:
Across the network, the company manufactures tablets, capsules, injections, drops, and ointments/external preparations, including formats such as oral jelly and aerosols. This provides a wide and integrated manufacturing base across oral solids, sterile injectables, and topical and liquid formulations.
Total production capacity:
The combined production capacity of the network is approximately 4.4 billion units annually, comprising around 2,012 million tablets, 1,857 million capsules, 515 million units of ointment and external preparations, 22 million drops, and 7 million injections.
Operational since 1990, the Vasai facility is HAB Pharma’s oldest manufacturing site. It consists of a single owned production block of approximately 1,200 square metres of built-up area on about 500 square metres of owned land and employs 119 people on roll. The facility operates as a compact and efficiently integrated oral solid manufacturing unit.
Dosage forms: Tablets and capsules. Production processes include granulation, compression, coating, capsule filling, and blending operations such as drum, octagonal, and dry blending. Packaging capabilities include blister packing across online and offline lines, supporting flexibility in packaging formats and batch sizes.
Annual capacity includes 672 million tablets and 226 million capsules. Output from this facility is supplied to South Asia, Africa, and Southeast Asia.
Established in 2008, Unit 2 is located in Selaqui, Uttarakhand, and operates across two blocks: Block A (owned, approximately 6,000 square metres) and Block B (leased, approximately 4,000 square metres). The unit is situated on a combination of owned and leased land and employs 257 people on roll, making it the largest facility by headcount. The dual-block structure enables the integration of multiple dosage forms and manufacturing capabilities within a single unit.
Dosage forms: Tablets, capsules, drops, and ointments/external preparations, including oral jelly and aerosol formats. Production processes include granulation, compression, coating, capsule filling, formulation manufacturing, eye drop filling, tube filling, and aerosol filling. Packaging capabilities include blister packing (online and offline), pouch sealing, and packaging for tube and aerosol products.
Annual capacity includes 832 million capsules, 582 million tablets, 450 million units of ointment and external preparations (including oral jelly and aerosols), and 22 million drops. This unit serves export markets across Latin America, Southeast Asia, South Asia, the Middle East, and Africa.
Operational since 2016, Unit 3 is the newest facility in the network and is located on the Selaqui campus. It is structured across three phases: Phase 1 Beta (owned, approximately 3,011 square metres), Phase 2 General (owned, approximately 4,324 square metres), and Phase 3 Cepha (leased, approximately 2,703 square metres). The unit employs 240 people on roll. This facility includes a dedicated sterile manufacturing suite, enabling in-house production of injectable formulations.
Dosage forms: Tablets, capsules, injections, and ointments/external preparations, including aerosol formats. Production processes:
Annual capacity includes 799 million capsules, 758 million tablets, 65 million units of ointment and external preparations, and 7 million injections. This unit supplies products to the Middle East, South Asia, Southeast Asia, and Africa.
HAB Pharma’s three manufacturing units provide integrated coverage across oral solids, sterile injectables, and topical and liquid formulations within a unified manufacturing network. Oral solid manufacturing capabilities, including granulation, compression, coating, capsule filling, and blister packing, are present across all three units, supporting operational flexibility and production alignment across sites. Sterile and liquid manufacturing capabilities are distributed across the network: injectable manufacturing processes, including vial washing, sterilization, filling, inspection, and labelling, are located in Unit 3; eye drop filling is carried out in Unit 2; and liquid, tube, and aerosol filling operations are present across both Unit 2 and Unit 3. Packaging capabilities include pouch sealing, blending operations, and flexible online and offline packaging lines, enabling efficient handling of varied production volumes and formats. In aggregate, the network’s annual production capacity comprises approximately 2,012 million tablets, 1,857 million capsules, 515 million units of ointment and external preparations, 22 million drops, and 7 million injections, representing a combined output of around 4.4 billion units across six production blocks.
All three facilities operate under a shared quality management framework rather than site-specific standards. In-process checks are built into each stage of production, granulation, compression, coating and filling, so deviations are caught at the point they occur rather than only at final release. Batch release itself is gated on documented inspection at every one of those stages, which keeps the release decision consistent regardless of which block or unit produced the batch.
All three units hold WHO-GMP and ISO 9001:2015 status, the baseline regulatory position across the network. Unit 2 is additionally pursuing CE marking, specifically for its nasal, ophthalmic, medical device and wound dressing lines, which would extend the network's regulatory reach into markets that require CE-marked medical devices alongside conventional pharmaceutical registrations. No USFDA or EU-GMP certification currently applies to the facilities described here.
Running a shared quality standard across three units, rather than a separate standard per site, has let HAB Pharma support repeat regulatory and customer audits without needing site-specific rework each time an auditor visits a different block. That consistency underpins the group's export reach into South Asia, Africa, Southeast Asia, Latin America and the Middle East, where customers and regulators alike expect the same documented process discipline whichever HAB Pharma facility a given batch was produced at.
Whether you’re evaluating HAB Pharma for contract manufacturing, checking available capacity for a specific dosage form, confirming certification for a regulated market, or simply want to see a plant in person, the facilities team can walk you through site-specific detail that isn’t captured in this overview, current line utilisation, lead times, and product-fit for your formulation.
